Novel combination for the treatment of aids
Assignee21C Bio
InventorDaniel ZAGURY
Life of this patent
Estimating the term…
Abstract
A method for treating acquired immune deficiency syndrome (AIDS) in a subject in need thereof. In particular, the method includes the administration of a combination, a kit-of-parts, a composition or a pharmaceutical composition including an interferon-alpha (IFN-α) blocking agent, a type III interferon blocking agent, an antiretroviral (ART) agent and, optionally, an interferon-beta (IFN-β) blocking agent and/or a latency-reversing agent (LRA).
Claims25
A method for treating acquired immune deficiency syndrome (AIDS) in an HIV-1 infected subject in need thereof, wherein said subject is under combined antiretroviral therapy (cART) comprising at least one antiretroviral (ART) agent, said method comprising administering to the subject a combination comprising:
- i) a type III interferon blocking agent,
- ii) interferon-alpha (IFN-α) blocking agent,
- iii) optionally, an interferon-beta (IFN-β) blocking agent,
- iv) said at least one antiretroviral (ART) agent, and
- v) optionally, a latency-reversing agent (LRA).
(canceled)
A kit-of-parts or a combination comprising:
- a) an interferon-alpha (IFN-α) blocking agent,
- b) a type III interferon blocking agent,
- c) optionally, an interferon-beta (IFN-β) blocking agent,
- d) the at least one antiretroviral (ART) agent, and
- e) optionally, a latency-reversing agent (LRA).
Dependencies are inferred from the claim text.